Lapatinib in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2

Author： Giordano Sara B   Kaklamani Virginia  

Publisher： Future Medicine

ISSN： 1758-1923

Source： Breast Cancer Management, Vol.2, Iss.6, 2013-11, pp. : 529-535

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase II study evaluating lapatinib in combination with nab -paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

By Yardley Denise  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 457-464

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 4, 2004-12 ,pp. : 277-278

Informa Healthcare

Access to resources Recommend Favorite

A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 1051-1059

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gemcitabine: In Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer

By Moen Marit D.   Wellington Keri  

American Journal of Cancer, Vol. 4, Iss. 5, 2005-01 ,pp. : 327-333

Adis International

Access to resources Recommend Favorite